View on GitHub

Added entries:

  • (Preclinical) ATM copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) BAP1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) BARD1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) CCNE1 copy number amplifications and sensitivity to dinaciclib in osteosarcoma.
  • (Preclinical) CDK4 copy number amplifications and sensitivity to palbociclib in osteosarcoma.
  • (Preclinical) CHEK2 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) FANCA copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) FGFR1 copy number amplifications and sensitivity to AZ4547 and PD173074 in osteosarcoma.
  • (Preclinical) MYC copy number amplifications and sensitivity to AT7519 in osteosarcoma.
  • (Preclinical) PTEN copy number deletions and sensitivity to MK-2206 and rapamycin in osteosarcoma.
  • (Preclinical) RB1 somatic variants and sensitivity to olaparib and palbociclib in osteosarcoma.
  • (Preclinical) TP53 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) TP53 somatic variants and sensitivity to NSC59984 in osteosarcoma.

Revised entries:

  • (FDA) ERBB2 amplifications in metastatic breast cancer were revised to list invasive breast carcinoma as the cancer type.
  • (FDA) TSC1 and TSC2 somatic variants and sensitivity to everolimus in subependymal giant cell astrocytoma were revised to include Oncotree terms and codes.
  • (Preclinical) AKT1 somatic variants and p.E17K and sensitivity to MK-2206 were revised to include breast cancer as the Oncotree terms and code. The description was also updated for both cataloged relationships.
  • (Preclinical) ATM p.A1127D, c.2251-10T>G, and shRNA knockdown and sensitivity to olaparib was revised to update the doi of the underlying journal article and properly list the Oncotree code.
  • (Preclinical) CDKN2A copy number deletions and sensitivity to EPZ015666 was adjusted to inferential evidence because the underlying relationship is for MTAP deletions, which are commonly co-deleted with CDKN2A.
  • (Preclinical) PTEN copy number deletions and somatic frameshift, nonsense, and splice site variants and sensitivity to AZD8186 were edited to add prostate cancer as the tumor type and the description was revised.
  • (Preclinical) RB1 shRNA knockdowns and resistance to palbociclib in prostate cancer was revised to properly list the Oncotree code and term.
  • (Inferential) COSMIC mutational signature 10 and sensitivity to pembrolizumab and durvalumab was revised to list any solid tumor as the cancer type.

publication_date was also added for all revised entries.

Removed entries:

  • (Preclinical) PIK3CB and sensitivity to AZD8186.